NASDAQ:MLYS Mineralys Therapeutics Q3 2026 Earnings Date & Estimates $22.59 -0.78 (-3.34%) As of 10:58 AM Eastern This is a fair market value price provided by Massive. Learn more. Mineralys Therapeutics is scheduled to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 9, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Mineralys Therapeutics in Q3 2026Mineralys Therapeutics is expected to post earnings of -$0.53 per share. In the same quarter a year earlier Mineralys Therapeutics reported -$0.52 per share. Mineralys Therapeutics last reported on August 12, 2026, posting -$2.85 per share and missing the -$0.5486 consensus estimate. Mineralys Therapeutics has beaten the consensus EPS estimate in 6 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.53Prior-Year EPS-$0.52Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$2.85 (Missed by -$2.3014)EPS Beat Rate6 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Mineralys Therapeutics Q3 2026 Earnings FAQ When does Mineralys Therapeutics report Q3 2026 earnings? Mineralys Therapeutics (NASDAQ:MLYS) is scheduled to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. What time is Mineralys Therapeutics' Q3 2026 earnings call? Mineralys Therapeutics' Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Mineralys Therapeutics? Analysts expect Mineralys Therapeutics to post earnings of -$0.53 per share for Q3 2026. Mineralys Therapeutics Earnings HeadlinesUBS Initiates Coverage on Mineralys Therapeutics With Neutral Rating, $29 Price Target1 hour ago | marketscreener.comMHC Wainwright Reaffirms Buy Rating for Mineralys Therapeutics (NASDAQ:MLYS)2 hours ago | americanbankingnews.comPalantir and Wall Street are in on it…Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has poured billions into this firm, which may have found a solution to the growing AI energy crunch. Unlike pricey chipmakers trading at 40 times earnings, this pure-play AI energy name remains cheap and profitable. See the name and ticker behind this fast-moving story before wider attention catches on.October 12 at 1:00 AM | Monument Traders Alliance (Ad)Mineralys Therapeutics, Inc. Presents New Data for Lorundrostat At the American Heart Association Hypertension Scientific Sessions 2026October 9 at 6:27 PM | marketscreener.comMMineralys Therapeutics, Inc. (MLYS) Presents at American Heart Association Hypertension Scientific Sessions 2026 - SlideshowOctober 9 at 1:30 PM | seekingalpha.comMineralys Therapeutics Announces Positive Lorundrostat Data From Launch-HTN and Explore-OSA Trials Show Meaningful Blood Pressure ReductionsOctober 9 at 9:31 AM | quiverquant.comQSee More Mineralys Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Mineralys Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mineralys Therapeutics and other key companies, straight to your email. Email Address About Mineralys TherapeuticsMineralys Therapeutics (NASDAQ:MLYS) is a clinical-stage biopharmaceutical company focused on developing medicines for hypertension and other cardiovascular and kidney-related conditions associated with excess aldosterone activity. The company is headquartered in Radnor, Pennsylvania. Mineralys’ lead product candidate is lorundrostat, an oral, highly selective aldosterone synthase inhibitor designed to reduce the production of aldosterone. The company is evaluating lorundrostat as a potential treatment for uncontrolled or resistant hypertension, including hypertension linked to abnormal activation of the renin-angiotensin-aldosterone system. Mineralys was established to advance therapies targeting aldosterone-driven disease and became a publicly traded company on the Nasdaq exchange in 2023. Its activities primarily center on pharmaceutical research and development and the clinical evaluation of lorundrostat; the company does not currently market an approved commercial product.View Mineralys Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Retail Picks to Watch as the Holiday Shopping Season NearsMarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsC.H. Robinson Bets Its AI Story on RXO—But the Market Isn't SoldApplied Digital’s Hidden Moat Could Unlock Massive Upside Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
